Hyun C. Chung, MD, PhD, Yonsei Cancer Center, Seoul, Republic of Korea, discusses the ongoing PANTHERA trial (NCT02901301), a multi-institutional Phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, and chemotherapy) for HER2-positive advanced gastric and gastroesophageal junction cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).